Home Cart Sign in  
Chemical Structure| 2140-46-7 Chemical Structure| 2140-46-7

Structure of 25-Hydroxycholesterol
CAS No.: 2140-46-7

Chemical Structure| 2140-46-7

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

25-Hydroxycholesterol is a potent and selective suppressor of IgA production by B cells wit EC50 about 65 nM.

Synonyms: 25-OHC

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of 25-Hydroxycholesterol

CAS No. :2140-46-7
Formula : C27H46O2
M.W : 402.65
SMILES Code : O[C@H](C1)CC[C@@]2(C)C1=CC[C@]3([H])[C@]2([H])CC[C@@]4(C)[C@@]3([H])CC[C@]4([H])[C@H](C)CCCC(O)(C)C
Synonyms :
25-OHC
MDL No. :MFCD00057815
InChI Key :INBGSXNNRGWLJU-ZHHJOTBYSA-N
Pubchem ID :65094

Safety of 25-Hydroxycholesterol

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H312-H315-H319-H332-H335-H373
Precautionary Statements:P261-P280-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
HEK293T cells 1µM 8h Inhibited VSV-GFP expression Immunity. 2013 Jan 24;38(1):92-105
Bovine aortic smooth muscle cells (BASMC) 1 μg/ml 24 days 25-Hydroxycholesterol did not induce nodule formation or calcification in BASMC. J Clin Invest. 1994 May;93(5):2106-13
Bovine aortic endothelial cells (BAEC) 1 μg/ml 24 days 25-Hydroxycholesterol did not induce nodule formation or calcification in BAEC. J Clin Invest. 1994 May;93(5):2106-13
Calcifying vascular cells (CVC) 1 μg/ml 24 days 25-Hydroxycholesterol significantly increased the number of mineralized nodules formed by CVC, which were highly calcified. J Clin Invest. 1994 May;93(5):2106-13
PBMCs (Peripheral Blood Mononuclear Cells) 0.5 or 1.0 μM 12 h To evaluate the inhibitory effect of 25-HC@DDAB on cytokine storm in PBMCs from COVID-19 patients. Results showed that 25-HC@DDAB significantly reduced levels of inflammatory cytokines such as IL-1β. Nano Today. 2021 Jun;38:101149
BM-derived macrophages (BMDM) 25 ng/ml 4 h To study the effect of 25-HC on lipid body formation, results showed that 25-HC induces lipid body formation. J Exp Med. 2012 Apr 9;209(4):807-17
Caco2 cells 0.07 to 16.7 µM 20 h Evaluate the inhibitory effect of 25HC and 27HC on HRV infection, results showed both significantly inhibited HRV infection. Redox Biol. 2018 Oct;19:318-330
MA104 cells 0.07 to 16.7 µM 20 h Evaluate the inhibitory effect of 25HC and 27HC on HRV infection, results showed both significantly inhibited HRV infection. Redox Biol. 2018 Oct;19:318-330
splenic B220+ cells 250 nM 6 days 25-Hydroxycholesterol suppressed IgA class switch recombination in B cells, particularly when exposed early Proc Natl Acad Sci U S A. 2009 Sep 29;106(39):16764-9
bone marrow-derived macrophages 500 nM 24 h TLR4 activation led to significant increases in 25-hydroxycholesterol and CH25H mRNA and protein levels Proc Natl Acad Sci U S A. 2009 Sep 29;106(39):16764-9
apoE4-expressing microglia 10 μg/ml 24 h apoE4-expressing microglia secrete higher levels of IL-1β after treatment with LPS and 25-HC J Neuroinflammation. 2020 Jun 17;17(1):192
Primary mouse microglia (PMG) 5 μg/ml 24 h To investigate the effect of 25HC on microglial phagocytic capacity, results showed that 25HC significantly reduced the phagocytic ability of microglia. J Neuroinflammation. 2025 Feb 25;22(1):50
CEM cells 5µM 12h Inhibited HIV entry Immunity. 2013 Jan 24;38(1):92-105
HeLa cells 1µM 5h Inhibited Ebola virus replication Immunity. 2013 Jan 24;38(1):92-105
PBMCs 1µM 24h Inhibited HIV NL4-3 p24 expression Immunity. 2013 Jan 24;38(1):92-105
J2 BMMs 1µM 12h Reduced VSV replication Immunity. 2013 Jan 24;38(1):92-105
Bone marrow-derived macrophages (BMDMs) 1 μM 24 h To evaluate the effect of 25-HC on IL-1β production after L. monocytogenes infection. Results showed that Ch25h−/− BMDMs produced more IL-1β, and this effect was inhibited by the addition of 25-HC. Cell. 2017 Nov 16;171(5):1057-1071. e11

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BL/6 mice Cecal ligation and puncture (CLP)-induced sepsis model Intravenous injection 1 μM Single dose, observed for 96 hours To evaluate the therapeutic effect of 25-HC@DDAB in a CLP-induced sepsis mouse model. Results showed that 25-HC@DDAB significantly improved survival rate (50%) and reduced inflammation and tissue damage. Nano Today. 2021 Jun;38:101149
Mouse 5XFAD transgenic mice Intraperitoneal injection 10 mg/kg Every other day for four weeks To investigate the effect of 25HC on Alzheimer's disease pathology, results showed that 25HC accelerated amyloid accumulation and exacerbated cognitive and behavioral deficits. J Neuroinflammation. 2025 Feb 25;22(1):50
C57BL/6 mice Myocardial ischemia-reperfusion injury model Intraperitoneal injection 10 mg/kg Single dose, 10 minutes before reperfusion 25-HC significantly reduced myocardial infarct size, improved cardiac function, and inhibited PARP activity. Int J Biol Sci. 2020 Jan 1;16(2):298-308
NRG-hu mice Humanized mouse model Intraperitoneal injection 50mg/kg Daily for 14 days Suppressed HIV replication and rescued T-cell depletion Immunity. 2013 Jan 24;38(1):92-105

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.48mL

0.50mL

0.25mL

12.42mL

2.48mL

1.24mL

24.84mL

4.97mL

2.48mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories